AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT by and between TEKMIRA PHARMACEUTICALS CORPORATION and ALNYLAM PHARMACEUTICALS, INC.License and Collaboration Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Delaware
This AMENDED AND RESTATED LICENSE AND COLLABORATION AGREEMENT, effective as of May 30, 2008, is made by and between Tekmira Pharmaceuticals Corporation (as successor in interest to INEX Pharmaceuticals Corporation (“INEX”)), a corporation organized and existing under the laws of British Columbia, Canada (“Tekmira”), and Alnylam Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, U.S.A (“Alnylam”).
AMENDED AND RESTATED LICENSE AGREEMENT BETWEEN INEX PHARMACEUTICALS CORPORATION AND HANA BIOSCIENCES, INC.License Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Washington
INEX PHARMACEUTICALS CORPORATION, a company duly incorporated under the laws of British Columbia having an office at #200 – 8900 Glenlyon Parkway, Burnaby, British Columbia, Canada V5J 5J8
AMENDED AND RESTATED CROSS-LICENSE AGREEMENT Between ALNYLAM PHARMACEUTICALS, INC. And PROTIVA BIOTHERAPEUTICS INC. Dated: May 30, 2008Cross-License Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Delaware
This Amended and Restated Cross-License Agreement (this “Agreement”) is entered into as of May 30, 2008, by and between ALNYLAM PHARMACEUTICALS, INC., a corporation organized under the laws of the State of Delaware having a principal office at 300 Third Street, Cambridge, MA 02142, U.S.A., and PROTIVA BIOTHERAPEUTICS INC., a Canadian corporation, having a principal office at 100-3480 Gilmore Way, Burnaby, B.C., Canada.
LICENSE AGREEMENT BETWEEN INEX PHARMACEUTICALS CORPORATION AND ARADIGM CORPORATIONLicense Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • British Columbia
This LICENSE AGREEMENT dated as of the 8th day of December, 2004 between INEX PHARMACEUTICALS CORPORATION, a corporation duly incorporated pursuant to the laws of British Columbia, CANADA, having its principal place of business at 100 – 8900 Glenlyon Parkway, Burnaby, B.C. Canada V5J 5J8 (hereinafter referred to as “INEX”), and ARADIGM CORPORATION, a corporation duly incorporated pursuant to the laws of the State of California, USA, having its principal place of business at 3929 Point Eden Way, Hayward, CA 94545 USA. (hereinafter referred to as “Aradigm”).
DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENTDevelopment, Manufacturing and Supply Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • Delaware
This Development, Manufacturing and Supply Agreement (the “Agreement”) is entered into as of January 2, 2009 (the “Effective Date”), by and between Alnylam Pharmaceuticals, Inc., a corporation duly incorporated and existing under the laws of the State of Delaware, U.S.A, (“Alnylam”), and Tekmira Pharmaceuticals Corporation, a corporation duly organized and existing under the laws of the Province of British Columbia, Canada (“Tekmira”).
ContractSublicense Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • British Columbia
* Confidential Treatment has been requested for the marked portions of this exhibit pursuant to Rule 24B-2 of the Securities Exchange Act of 1934, as amended.
SETTLEMENT AGREEMENTSettlement Agreement • January 31st, 2012 • TEKMIRA PHARMACEUTICALS Corp • Pharmaceutical preparations • New York
This Settlement Agreement (“Settlement Agreement” or “Agreement”) sets forth the terms upon which Sirna Therapeutics, Inc. (SIRNA) and Merck & Co., Inc. (“MERCK & CO”) and Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc. (collectively “PROTIVA”) agree to settle the litigations pending both before the Superior Court of California, San Francisco County, captioned Protiva Biotherapeutics, Inc. et. al. v. Sirna Therapeutics, Inc., Case No. CGC-06-450694 and before the United States District Court For The Northern District of California, captioned Sirna Therapeutics, Inc. v. Protiva Biotherapeutics, Inc. and Mark J. Murray, Case No. C-06-1361 (MMC) (collectively the “Litigation”). SIRNA, MERCK & CO and PROTIVA are individually referred to in this Agreement as a “Party” and collectively as the “Parties”. This Agreement shall be effective as of October 9, 2007 (“Effective Date”).
